How Can a Drug Pair Revive Memory in Obese Rats?

Obesity isn’t just a weight issue; it also impairs the brain, especially the prefrontal cortex, which handles learning and memory. To test whether two drugs could counteract these effects, researchers used Lewis rats fed a high‑fat diet until they became obese. The animals received a 30‑day combo of lorcaserin, a 5‑HT2C agonist, and betahistine, an H1 agonist/H3 antagonist, delivered via implanted osmotic minipumps.

Three behavioral tests measured cognition: the Y‑maze, novel object recognition, and the object‑in‑place (OIP) test, the latter being highly sensitive to prefrontal function. Obese rats scored lower on the OIP, while performing like controls on the first two tests. When both drugs were given together, OIP scores of obese rats improved markedly, approaching those of normal‑weight controls.

Body weight and obesity‑related measurements did not change. Yet electrophysiological recordings showed that obese rats had fewer spontaneously active dopaminergic neurons in the ventral tegmental area (VTA). The lorcaserin‑betahistine combo increased the number of active VTA dopamine cells, suggesting that cognitive recovery may stem from boosted mesocortical dopamine activity. In short, this combined therapy can reverse obesity‑related cognitive deficits, hinting at new brain‑focused treatment strategies.

The diet‑induced obesity (DIO) model is widely employed to mimic the metabolic and neurocognitive alterations seen in humans. Lorcaserin is a selective serotonin 5‑HT2C receptor agonist, known to modulate appetite via the hypothalamus, but also to affect dopaminergic transmission in the mesocortical pathway. Betahistine, on the other hand, acts as an H1 agonist and H3 antagonist; the latter functions as an inhibitory autoreceptor for neurotransmitter release, including dopamine.

Pharmacologically, the two compounds may produce a synergistic effect: lorcaserin reduces hypothalamic dopaminergic neuron activity, increasing dopamine availability in the prefrontal cortex, while betahistine, by blocking H3, enhances dopamine release from cortical terminals. This mechanism aligns with electrophysiological recordings showing an increased number of spontaneously active VTA dopamine neurons after combined treatment.

Synaptically, heightened dopaminergic activity can facilitate cortical plasticity, improving the consolidation and retrieval of spatial information, as reflected by better OIP task performance. Dopamine also modulates attention and motivation, processes often impaired in obesity.

Although body weight remained unchanged, the normalization of dopaminergic function suggests that cognitive deficits are not solely driven by excess adiposity but also by reversible neurochemical alterations. Future work should investigate the durability of the effect, dose‑response relationships, and translation to more complex models, including clinical trials in humans with obesity‑related cognitive impairment.